GlaxoSmithKline's (GSK) VC fund, SR One, is looking to invest in a company that is developing...

|About: GlaxoSmithKline (GSK)|By:, SA News Editor

GlaxoSmithKline's (GSK) VC fund, SR One, is looking to invest in a company that is developing drugs for the early detection of Alzheimer’s disease and a treatment for it. Separately, GSK is applying Shinya Yamanaka’s Nobel Prize-winning discovery in stem cells to help find out if experimental drugs have heart risks. Around half of drugs that fail due to safety do so because of the effects on the heart.